TY - JOUR
T1 - Ejaculatory dysfunction following prostate artery embolization
T2 - A retrospective study utilizing the male sexual health questionnaire-ejaculation dysfunction questionnaire
AU - Young, Shamar
AU - Moran, Patrick
AU - Golzarian, Jafar
N1 - Publisher Copyright:
© 2022 Société française de radiologie
PY - 2022/6
Y1 - 2022/6
N2 - Purpose: The purpose of this study was to determine the rate of ejaculatory dysfunction that develops following prostate artery embolization (PAE) and identify predictive factors. Materials and methods: Thirty-nine men (mean age, 67.9 ± 8.1 ([SD)] years; range: 52–84 years) who underwent PAE were retrospectively asked to complete the male sexual health questionnaire-ejaculation dysfunction (MSHQ-EjD) short form. Pre-treatment, procedural, and post-treatment variables were also collected. Results: A total of four patients (4/39, 10.3%) developed ejaculatory dysfunction following PAE, with one (1/4, 25%) reporting improvement in his ejaculatory dysfunction over time. When evaluating the group as a whole there was no significant difference between the pre and post-treatment answers of patients when asked about how often they ejaculate when having sexual activity (P = 0.77), strength of ejaculation (P = 0.86), or volume of ejaculation (P = 0.67). Similarly, the total MHSQ-EjD score was not different when evaluating the group as a whole pre (11.4 ± 5.3 [SD]; range: 1–15) and post-treatment (10.7 ± 5.3 [SD]; range: 1–15) (P = 0.54), nor was the degree of bother from ejaculatory difficulties significantly different (0.82 ± 1.1 [SD]; range: 0–5 vs. 1 ± 1.1 [SD]; range: 0–5; P = 0.9). When comparing those who did to those who did not develop ejaculatory dysfunction, univariable analysis demonstrated that post void residual volume was significantly greater in those who did develop dysfunction (median, 202 mL; IQR: 274; range: 40–588) than in those who did not (median, 58 mL; IQR: 124; range: 0–408) (P = 0.04). Conclusion: We found that 10.3% of patients undergoing PAE develop ejaculatory dysfunction and those with greater post void residual volume may be at increased risk. However, the data should be interpreted with caution given the small sample size and more, preferably prospective, data are needed to determine the true rates of ejaculatory dysfunction following PAE.
AB - Purpose: The purpose of this study was to determine the rate of ejaculatory dysfunction that develops following prostate artery embolization (PAE) and identify predictive factors. Materials and methods: Thirty-nine men (mean age, 67.9 ± 8.1 ([SD)] years; range: 52–84 years) who underwent PAE were retrospectively asked to complete the male sexual health questionnaire-ejaculation dysfunction (MSHQ-EjD) short form. Pre-treatment, procedural, and post-treatment variables were also collected. Results: A total of four patients (4/39, 10.3%) developed ejaculatory dysfunction following PAE, with one (1/4, 25%) reporting improvement in his ejaculatory dysfunction over time. When evaluating the group as a whole there was no significant difference between the pre and post-treatment answers of patients when asked about how often they ejaculate when having sexual activity (P = 0.77), strength of ejaculation (P = 0.86), or volume of ejaculation (P = 0.67). Similarly, the total MHSQ-EjD score was not different when evaluating the group as a whole pre (11.4 ± 5.3 [SD]; range: 1–15) and post-treatment (10.7 ± 5.3 [SD]; range: 1–15) (P = 0.54), nor was the degree of bother from ejaculatory difficulties significantly different (0.82 ± 1.1 [SD]; range: 0–5 vs. 1 ± 1.1 [SD]; range: 0–5; P = 0.9). When comparing those who did to those who did not develop ejaculatory dysfunction, univariable analysis demonstrated that post void residual volume was significantly greater in those who did develop dysfunction (median, 202 mL; IQR: 274; range: 40–588) than in those who did not (median, 58 mL; IQR: 124; range: 0–408) (P = 0.04). Conclusion: We found that 10.3% of patients undergoing PAE develop ejaculatory dysfunction and those with greater post void residual volume may be at increased risk. However, the data should be interpreted with caution given the small sample size and more, preferably prospective, data are needed to determine the true rates of ejaculatory dysfunction following PAE.
KW - Benign prostatic hyperplasia
KW - Ejaculatory dysfunction
KW - Lower urinary tract symptoms
KW - Prostate artery embolization
UR - http://www.scopus.com/inward/record.url?scp=85123724943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123724943&partnerID=8YFLogxK
U2 - 10.1016/j.diii.2022.01.003
DO - 10.1016/j.diii.2022.01.003
M3 - Article
C2 - 35086788
AN - SCOPUS:85123724943
SN - 2211-5684
VL - 103
SP - 310
EP - 315
JO - Diagnostic and Interventional Imaging
JF - Diagnostic and Interventional Imaging
IS - 6
ER -